As Vaccine Revenues Flow In, BioNTech Makes Rapid Oncology Push
German Biotech Initiates Multiple IO Programs
The company also is adding new capabilities, including a cell therapy platform, and it is investing in AI and machine learning, like fellow mRNA player and COVID-19 vaccine maker Moderna.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: a history of Alzheimer’s drug development; BioNTech looks beyond COVID-19 vaccines; gene therapy setbacks for bluebird; new promise for Roche’s Polivy in B-cell lymphoma; and rising US momentum for US drug price negotiations.
Moderna may benefit from data indicating strong efficacy against the Delta strain, though an analyst pointed out that they come with some important caveats.
Reports indicate a 13 August CDC advisory committee meeting may be used to address an amended FDA emergency use authorization to allow immunosuppressed Americans to get additional COVID-19 vaccine doses. Such a move would not run afoul of the World Health Organization’s plea for a moratorium on boosters in the general population until much of the world initially can be vaccinated.